Xolair Enhances Oral Desensitization in Peanut Allergic Patients

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Lynda Schneider
Study ID
NCT01290913
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Peanut Allergy

Eligibility Criteria

Sex
ALL
Age
7 Years - 25 Years
Healthy Volunteers
Not accepted

Interventions

  • Omalizumab — DRUG
    Omalizumab is an antibody that helps decrease allergic responses in the body

Study Details

This is a pilot feasibility study, using Xolair pretreatment for oral peanut desensitization.

Key Dates

Start date
Feb 28, 2011
Status verified
Mar 2015
Primary completion
Sep 30, 2013
Completion
Sep 30, 2013

Study Design

Enrollment
13 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: omalizumab, oral desensitization
    Patients receive omalizumab along with oral peanut desensitization.

Primary Outcome Measure

Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 500 mg Peanut Flour (Cumulative Dose, 1,000 mg) [ Time Frame: First day of desensitization ]

Locations (1)

FacilityCityStateZIPSite coordinators
Children's Hospital Boston, Harvard Medical SchoolBostonMassachusetts02115-

Find similar trials in Boston, MA

By research site
Children's Hospital Boston, Harvard Medical School· Boston, MA

Related Studies